[HTML][HTML] Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort… - ERJ Open …, 2022 - Eur Respiratory Soc
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
RGP Gijtenbeek, V van der Noort, J Aerts… - ERJ Open …, 2022 - europepmc.org
Materials and methods Treatment-naïve patients with an activating EGFR mutation, ECOG
performance score of 0-3 and adequate organ function were randomly assigned 1: 1 to …
performance score of 0-3 and adequate organ function were randomly assigned 1: 1 to …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort, JGJV Aerts… - ERJ Open …, 2022 - research.rug.nl
Introduction: Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
[HTML][HTML] Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort, JGJV Aerts… - ERJ Open …, 2022 - ncbi.nlm.nih.gov
Materials and methods Treatment-naïve patients with an activating EGFR mutation, ECOG
performance score of 0–3 and adequate organ function were randomly assigned 1: 1 to …
performance score of 0–3 and adequate organ function were randomly assigned 1: 1 to …
[PDF][PDF] Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort, JGJV Aerts… - 2022 - pure.eur.nl
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort… - ERJ open …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
[PDF][PDF] Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort, JGJV Aerts… - 2022 - scholarlypublications …
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V Noort, J Aerts… - ERJ Open …, 2022 - scholarlypublications …
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
RGP Gijtenbeek, V van der Noort, J Aerts… - ERJ Open …, 2022 - europepmc.org
Materials and methods Treatment-naïve patients with an activating EGFR mutation, ECOG
performance score of 0-3 and adequate organ function were randomly assigned 1: 1 to …
performance score of 0-3 and adequate organ function were randomly assigned 1: 1 to …
[PDF][PDF] Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort, JGJV Aerts… - 2022 - pure.eur.nl
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …